Literature DB >> 34097464

HIV Risk and Pre-Exposure Prophylaxis Eligibility Among Emergency Department Patients.

Jason S Haukoos1,2,3, Douglas A E White4, Sarah E Rowan5,6, Carolynn Lyle1, Stephanie Gravitz1, Kellie Basham4, Ashley Godoy4, Kevin Kamis6, Emily Hopkins1,2, Erik Anderson4.   

Abstract

Our objective was to estimate the prevalence of pre-exposure prophylaxis (PrEP) eligibility, characterize self-perceived and quantified human immunodeficiency virus (HIV) risk, and assess PrEP knowledge and receptiveness of initiating PrEP among emergency department (ED) patients. We performed an IRB-approved cross-sectional study from two urban EDs. Patients were eligible if ≥18 years of age and not known to have HIV. Research staff obtained verbal consent and used a structured 29-item instrument to assess HIV risk, PrEP eligibility based on 2017 Centers for Disease Control and Prevention (CDC) guidelines, and general PrEP knowledge among unselected and enriched patient samples, the latter informed by the Denver HIV Risk Score (DHRS). We enrolled 1002 patients with a median age of 39 years; 54.8% were male, 30.9% White/non-Hispanic, 29.5% Black/non-Hispanic, and 22.5% Hispanic. In the full cohort, 119 [11.9%, 95% confidence interval (CI): 9.9-14.0%] were PrEP eligible, and among the unselected cohort, 36 (7.1%, 95% CI: 5.1-9.8%) were PrEP eligible. Using the DHRS, 100 patients were considered "high risk" with 32 (32.0%) reporting zero perceived risk. Correlation between the DHRS and self-perceived HIV risk was low (r = 0.13). Of the full cohort, 203 (20.3%) had heard of PrEP, and of these, 33 (16.3%) were PrEP eligible with 25 (75.8%) willing to start PrEP immediately. Yet, of the 119 patients who were PrEP eligible, only 34 (28.6%) had heard of PrEP. In summary, among a heterogeneous ED population, there was discordance in self-perceived and quantified HIV risk. HIV PrEP eligibility was ∼7% with the highest eligibility among those identified as DHRS "high risk." A significant opportunity exists to identify and initiate PrEP among ED patients.

Entities:  

Keywords:  Denver HIV Risk Score; HIV; HIV risk; emergency department; identification; pre-exposure prophylaxis; prevalence; prevention

Mesh:

Substances:

Year:  2021        PMID: 34097464      PMCID: PMC8336194          DOI: 10.1089/apc.2021.0012

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.944


  26 in total

1.  The impact of nontargeted HIV screening in emergency departments and the ongoing need for targeted strategies.

Authors:  Jason S Haukoos
Journal:  Arch Intern Med       Date:  2011-10-24

2.  Brief report: Validation of a quantitative HIV risk prediction tool using a national HIV testing cohort.

Authors:  Jason S Haukoos; Emily Hopkins; Meggan M Bucossi; Michael S Lyons; Richard E Rothman; Douglas A E White; Alia A Al-Tayyib; Lucy Bradley-Springer; Jonathan D Campbell; Allison L Sabel; Mark W Thrun
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

3.  Derivation and validation of the Denver Human Immunodeficiency Virus (HIV) risk score for targeted HIV screening.

Authors:  Jason S Haukoos; Michael S Lyons; Christopher J Lindsell; Emily Hopkins; Brooke Bender; Richard E Rothman; Yu-Hsiang Hsieh; Lynsay A Maclaren; Mark W Thrun; Comilla Sasson; Richard L Byyny
Journal:  Am J Epidemiol       Date:  2012-03-19       Impact factor: 4.897

4.  Targeted Screening for HIV Pre-Exposure Prophylaxis Eligibility in Two Emergency Departments in Washington, DC.

Authors:  Paige Kulie; Amanda D Castel; Zhaonian Zheng; Natasha N Powell; Aneil Srivastava; Sandhya Chandar; Melissa L McCarthy
Journal:  AIDS Patient Care STDS       Date:  2020-12       Impact factor: 5.078

5.  Which Patients in the Emergency Department Should Receive Preexposure Prophylaxis? Implementation of a Predictive Analytics Approach.

Authors:  Jessica P Ridgway; Ellen A Almirol; Alvie Bender; Andrew Richardson; Jessica Schmitt; Eleanor Friedman; Nicola Lancki; Ivan Leroux; Nina Pieroni; Jessica Dehlin; John A Schneider
Journal:  AIDS Patient Care STDS       Date:  2018-04-19       Impact factor: 5.078

6.  Contrasting Self-Perceived Need and Guideline-Based Indication for HIV Pre-Exposure Prophylaxis Among Young, Black Men Who Have Sex with Men Offered Pre-Exposure Prophylaxis in Atlanta, Georgia.

Authors:  Annie Lockard; Eli S Rosenberg; Patrick S Sullivan; Colleen F Kelley; David P Serota; Charlotte-Paige M Rolle; Nicole Luisi; Emily Pingel; Aaron J Siegler
Journal:  AIDS Patient Care STDS       Date:  2019-03       Impact factor: 5.078

7.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Authors:  Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

8.  Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Kachit Choopanya; Michael Martin; Pravan Suntharasamai; Udomsak Sangkum; Philip A Mock; Manoj Leethochawalit; Sithisat Chiamwongpaet; Praphan Kitisin; Pitinan Natrujirote; Somyot Kittimunkong; Rutt Chuachoowong; Roman J Gvetadze; Janet M McNicholl; Lynn A Paxton; Marcel E Curlin; Craig W Hendrix; Suphak Vanichseni
Journal:  Lancet       Date:  2013-06-13       Impact factor: 79.321

9.  Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States.

Authors:  Lisa A Grohskopf; Kata L Chillag; Roman Gvetadze; Albert Y Liu; Melanie Thompson; Kenneth H Mayer; Brandi M Collins; Sonal R Pathak; Brandon Oʼhara; Marta L Ackers; Charles E Rose; Robert M Grant; Lynn A Paxton; Susan P Buchbinder
Journal:  J Acquir Immune Defic Syndr       Date:  2013-09-01       Impact factor: 3.731

10.  Preexposure prophylaxis guidelines have low sensitivity for identifying seroconverters in a sample of young Black MSM in Chicago.

Authors:  Nicola Lancki; Ellen Almirol; Leigh Alon; Moira McNulty; John A Schneider
Journal:  AIDS       Date:  2018-01-28       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.